Scott Burwell is the founder and CEO of Neurotype which makes a portable EEG headset, the NeuromarkR, which quantifies brain physiological responses to possible triggers for people with Substance Use Disorder. This enables the recognition of brain biomarker targets for treatment and tracking changes over the course of recovery.
Top 3 Takeaways:
- "What we're trying to do is use these brain sensing devices to measure some objective biomarkers that can help make objective decisions. And objective treatment benchmarks accessible in addiction clinics."
- "This is really a risk biomarker and a way to stratify patients based on their risk, but it's also potentially a way to provide therapy and engagement practices with."
- "Patients aren't always aware of their own level of craving and their own level of vulnerability for relapse."
1:00 Do you want to introduce yourself?
3:15 "So let's talk a little bit, how you got into this"
5:45 "Do you wanna describe the technology a little bit? How it works, why it works?"
8:30 "It wouldn't be necessarily something that you take home? This would be like with the trained experts, something like this?"
9:30 "Can you also see the physiological side of things or is it, this is more like a psychological measurement?"
11:00 "So you've been around for two years. What are some good results, the best results that you've gotten so far?"
14:15 "Could you pair it with a, like an electroshock therapy to maybe disassociate that, that love?"
16:00 "What what are the next few years look like? What do you hope to achieve? "
18:00 "What have been some of your biggest challenges in in your company so far?"
21:00 "Is there anything that we didn't talk about that you wanted to mention?"